Semax and WADA: Is It Prohibited in Sport?

Semax is not explicitly named on the current WADA Prohibited List^[1]. That single sentence, however, does not give a competing athlete a clean bill of health. The Prohibited List contains catch-all language that can cover substances not individually named, and the classification of semax under those provisions is genuinely ambiguous. Athletes, coaches, and medical staff who need certainty before competition must understand exactly why the question is unsettled.

Where semax sits on the WADA Prohibited List

WADA's Prohibited List is organised into sections. The two most relevant to semax are S0 and S2. Section S0 covers non-approved substances: any pharmacological substance with no current approval by a recognised national or regional regulatory authority for human therapeutic use^[1]. Section S2 covers peptide hormones, growth factors, related substances, and mimetics, and includes a broad catch-all for substances with similar chemical structure or biological effect to those listed.

Semax is a registered prescription medicine in Russia, approved as a nasal spray for ischemic stroke recovery and cognitive disorders^[2]. Because it holds a national marketing authorisation in Russia, it does not fit the S0 definition cleanly: S0 targets substances with no recognised approval anywhere. A substance that is a licensed medicine in one country occupies genuinely uncertain territory under S0.

The 'related substances' catch-all and what it means for semax

Section S2 of the Prohibited List captures peptide hormones and their derivatives, including growth hormone, erythropoietin, insulin-like growth factor 1, and ACTH (adrenocorticotropic hormone)^[1]. The list does not stop at named substances. The S2 catch-all extends to substances with similar structure or biological effect to any prohibited compound. Semax is a synthetic heptapeptide built on the ACTH(4-7) fragment of full-length ACTH^[3]. On paper, that structural derivation from ACTH could place it within the S2 net.

The complication is functional. Full-length ACTH is prohibited because it stimulates the adrenal cortex to produce cortisol, giving athletes an unfair recovery and anti-inflammatory advantage. Semax retains the ACTH(4-7) amino-acid sequence but lacks the adrenal-stimulating activity^[3]. The Pro-Gly-Pro tail added to Semax further distinguishes it mechanistically from adrenocorticotropic hormone. Whether a WADA analyst or tribunal would treat that functional divergence as sufficient to exclude it from the S2 catch-all is a question with no published ruling to settle it.

This is the distinction the brief calls 'rare': the difference between being named as a prohibited substance (unambiguous) and being potentially swept up by structural catch-all language (ambiguous, and only resolved through a formal determination or an enforcement proceeding).

USADA guidance and enforcement context

USADA directs athletes to the WADA Prohibited List and to GlobalDRO for substance checks. Neither the USADA sanctions database nor the published anti-doping literature contains an enforcement case specifically naming semax^[1]. The absence of a case is not a clearance: it reflects the fact that semax testing methods are not reported in the doping-control literature, and that no athlete has yet been sanctioned specifically for this compound under WADA jurisdiction.

The enforcement precedent that exists is on structurally related peptides, not semax itself. ACTH (full-length) has been involved in doping cases in horse racing. Several growth-factor-related peptides have generated USADA sanctions in recent years. Those cases establish that the S2 catch-all is enforced actively, not merely written into the document as a precautionary measure.

An athlete seeking certainty should contact their national anti-doping authority directly, or use the WADA TUE (Therapeutic Use Exemption) consultation route if there is a medical need. There is no shortcut: the only authoritative answer comes from the relevant authority, not from an article or a vendor FAQ. USADA's drug reference line can be reached at +1 (719) 785-2000^[1].

What we do not yet know

Three gaps matter specifically for athletes. First, there is no published doping-control method for semax in biological samples, which means it is unclear whether anti-doping laboratories currently test for it^[4]. Second, the half-life and detection window in urine or blood are not described in the open scientific literature. Third, there has been no formal written determination from WADA confirming or denying that semax falls within S2.

Those three absences do not neutralise the risk. WADA can conduct research and development testing for substances before announcing a formal ban, and athletes are responsible for any prohibited substance found in their sample regardless of whether the substance was targeted in routine screening.

The semax peptide page covers the full evidence picture: mechanism, the Russian regulatory history, the Western approval gap, and the grey-market supply situation. If you are an athlete who has been prescribed semax by a Russian-trained clinician, or who is considering it for recovery support, the first call should be to your anti-doping authority, not to a vendor. The evidence on cognitive and neuroprotective effects is interesting^[2], but no performance benefit outweighs the risk of an unresolved anti-doping status.

This article is for education. It does not constitute legal or medical advice, and it does not reflect a determination by any anti-doping authority. Consult a sports medicine clinician and your national anti-doping organisation before using any substance with unclear Prohibited List status.